According to the research reports made on the patients who had a hip fracture from 2005 through 2013 were followed until late 2016. 4602(13%) of total 34,991 patients were given osteoporosis treatment during follow-up.
The patients who have undergone osteoporosis treatment they faced reduced risk of cardiovascular death, heart attack, and stroke, proved in a study of patients with hip fractures. The association of researchers was seen for up to 10 years after fracture.
Researchers connected Alendronate with 67% and 45% lower risks of one-year cardiovascular death and heart attack, respectively. Senior author Ching-Lung Cheung said that it is well known that there is a worldwide lack in the treatment of osteoporosis, as patients are not aware with the rare side effects. Researchers’ work report proved that alendronate is potentially cardioprotective in hip fracture patients.
Therefore, doctors should start prescribing alendronate or other nitrogen-containing bisphosphonates to the hip fractured patients immediately after their fracture, and patients should also have good compliance with alendronate treatment, as this is not only good for their bones but also for their heart.
This complete research study is published in the Journal of Bone and Mineral Research.